The starting dose of levothyroxine in primary hypothyroidism treatment: A prospective, randomized, double-blind trial

Archives of Internal Medicine

Volumn 165, Issue 15, 2005, Pages 1714-1720

  Roos, Annemieke ^a   Linn Rasker, Suzanne P ^a   Van Domburg, Ron T ^b   Tijssen, Jan P ^c   Berghout, Arie ^a  

^a Medisch Centrum Rijnmond Zuid   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOTHYROXINE; THYROTROPIN; THYROXINE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BICYCLE ERGOMETRY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; EUTHYROIDISM; FEMALE; FREE THYROXINE INDEX; HEART DISEASE; HUMAN; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; QT PROLONGATION; QUALITY OF LIFE; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SINUS BRADYCARDIA; THYROTROPIN BLOOD LEVEL; THYROXINE BLOOD LEVEL;

ADULT; AGED; DOUBLE-BLIND METHOD; HALF-LIFE; HUMANS; HYPOTHYROIDISM; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; QUALITY OF LIFE; THYROTROPIN; THYROXINE;

EID: 23744504435     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.165.15.1714     Document Type: Article

References (39)

1. Esposito S, Prange AJ, Golden RN. The thyroid axis and mood disorders: overview and future prospects. Psychopharmacol Bull. 1997;33:205-217.
2. Duyff RF, Van den Bosch J, Laman DM, van Loon BJ, Linssen WH. Neuromuscular findings in thyroid dysfunction: a prospective clinical and electrodiagnostic study. J Neurol Neurosurg Psychiatry. 2000;68:750-755.
3. Tielens ET, Pillay M, Storm C, Berghout A. Changes in cardiac function at rest before and after treatment in primary hypothyroidism. Am J Cardiol. 2000;85:376-380.
4. Diekman T, Demacker PNM, Kastelein JJP, Stalenhoef AFH, Wiersinga WM. Increased oxidizability of low-density lipoproteins in hypothyroidism. J Clin Endocrinol Metab. 1998;83:1752-1755.
5. Fommei E, Iervasi G. The role of thyroid hormone in blood pressure homeostasis: evidence from short-term hypothyroidism in humans. J Clin Endocrinol Metab. 2002;87:1996-2000.
6. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med. 1998;338:1042-1050.
7. Cappola AR, Ladenson PW. Hypothyroidism and atherosclerosis. J Clin Endocrinol Metab. 2003;88:2438-2444.
8. Lindsay RS, Toft AD. Hypothyroidism. Lancet. 1997;349:413-417.
9. Mandel SJ, Brent GA, Larsen PR. Levothyroxine therapy in patients with thyroid disease. Ann Intern Med. 1993;119:492-502.
10. Toft AD. Thyroxine therapy. N Engl J Med. 1994;331:174-180.
11. Singer PA, Cooper DS, Levy EG, et al. Treatment guidelines for patients with hyperthyroidism and hypothyroidism. JAMA. 1995;273:808-812.
12. Nieuwenhuijzen Kruseman AC, Geelhoed-Duijvesteijn PH. Substitutie therapie bij hypothyreoidie. Ned Tijdschr Geneeskd. 1987;131:1803-1807.
13. Roberts CGP, Ladenson PW. Hypothyroidism Lancet. 2004;363:793-803.
14. Smyth CJ. Angina pectoris and myocardial infarction as complications of myxedema: with especial reference to the danger of treatment with thyroid preparations. Am Heart J. 1938;15:652-660.
15. Becker C. Hypothyroidism and atherosclerotic heart disease: pathogenesis, medical management, and the role of coronary artery bypass surgery. Endocr Rev. 1985;6:432-440.
16. Ridgway EC, McCammon JA, Benotti J, Maloof F. Acute metabolic responses in myxedema to large doses of intravenous L-thyroxine. Ann Intern Med. 1972;77:549-555.
17. Keating FR, Parkin TW, Selby JB, Dickinson LS. Treatment of heart disease associated with myxedema. Prog Cardiovasc Dis. 1961;3:364-381.
18. Levine HD. Compromise therapy in the patients with angina pectoris and hypothyroidism: a clinical assessment. Am J Med. 1980;69:411-417.
19. Leonard JL, Visser TJ. Biochemistry of deiodination. In: Hennemann G, Dekker M, eds. Thyroid Hormone Metabolism. New York, NY: Marcel Dekker; 1986:189-229.
20. Salvatore D, Bartha T, Harney JW, Larsen PR. Molecular, biological and biochemical characterization of the human type 2 selenodeiodinase. Endocrinology. 1996;137:3308-3315.
21. Croteau W, Davey JC, Galton VA, St Germain DL. Cloning of the mammalian type II iodothyronine deiodinase: a selenoprotein differentially expressed and regulated in human and rat brain and other tissues. J Clin Invest. 1996;98:405-417.
22. Wagner MS, Morimoto R, Dora JM, Benneman A, Pavan R, Maia AL. Hypothyroidism induces type 2 iodothyronine deiodinase expression in mouse heart and testis. J Mol Endocrinol. 2003;31:541-550.
23. Fish LH, Schwartz HL, Cavanaugh J, Steffes MW, Bantle JP, Oppenheimer JH. Replacement dose, metabolism, and bioavailability of levothyroxine in the treatment of hypothyroidism. N Engl J Med. 1987;316:764-770.
24. Trantow T, Herzog R, Gegenheimer L, Lücker PW. A new method for the determination of the bioavailability of thyroid hormone preparations. Methods Find Exp Clin Pharmacol. 1994;16:133-140.
25. Zulewski H, Müller B, Exer P, Miserez AR, Staub J-J. Estimation of tissue hypothyroidism by a new clinical score: evaluation of patients with various grades of hypothyroidism and controls. J Clin Endocrinol Metab. 1997;82:771-776.
26. Lazarus JH, Hall R, Othman S, et al. The clinical spectrum of postpartum thyroid disease. QJM. 1996;89:429-435.
27. Van der Zee KI, Sanderman R. Het Meten van de Algemene Gezondheidstoestand met de RAND-36, een Handleiding. Groningen, the Netherlands: Noordelijk Centrum voor Gezondheidsvraagstukken, Rijks Universiteit Groningen; 1993.
28. Fisch C. Electrocardiography and vectorcardiography. In: Braunwald E, ed. Heart Disease: A Textbook for Cardiovascular Medicine. 4th ed. Philadelphia, Pa: WB Saunders; 1992:116-152.
29. Geleijnse ML, Fioretti PM, Roelandt JRTC. Methodology, feasibility, safety and diagnostic accuracy of dobutamine stress echocardiography. J Am Coll Cardiol. 1997;30:595-606.
30. Roos A, Zoet-Nugteren SK, Berghout A. Evaluation of cardiac ischaemia in cardiac asymptomatic newly diagnosed untreated patients with primary hypothyroidism. Neth J Med. 2005;63:97-102.
31. Robles de Medina EO, Daniels MCG, Sippens Groenewegen A. Electrocardiography. In: Roelandt JRTC, Lie KI, Wellens HJJ, Van De Werf F. Leerboek Cardiologie. Houten, the Netherlands: Bohn Stafleu Van Loghum; 1995:111-116.
32. Deckers JW, Rensing BJ, Tijssen JGP, Vinke RVH, Azar AJ, Simoons ML. A comparison of methods of analyzing exercise tests for diagnosis of coronary artery disease. Br Heart J. 1989;62:438-444.
33. Spencer CA, LoPresti JS, Nicoloff JT, Dlott R, Schwarzbein D. Multiphasic thyrotropin responses to thyroid hormone administration in man. J Clin Endocrinol Metab. 1995;80:854-859.
34. Wenzel KW, Kirschsieper HE. Aspects of the absorption of oral L-thyroxine in normal man. Metabolism. 1977;26:1-8.
35. Canaris GJ, Manowitz NR, Mayor G, Rigdway EC. The Colorado disease prevalence study. Arch Intern Med. 2000;160:526-534.
36. Helfand M, Crapo LM. Monitoring therapy in patients taking levothyroxine. Ann Intern Med. 1990;113:450-454.
37. Helfand M; U.S. Preventive Services Task Force. Screening for subclinical thyroid dysfunction in nonpregnant adults: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2004;140:128-141.
38. Escobar-Morreale HF, Obregon MJ, Escobar del Rey F, Morreale de Escobar G. Replacement therapy for hypothyroidism with thyroxine alone does not ensure euthyroidism in all tissues, as studied in thyroidectomized rats. J Clin Invest. 1995;96:2828-2838.
39. Bianco AC, Salvatore D, Gereben B, Berry MJ, Larsen PR. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases. Endocr Rev. 2002;23:38-89.